Medtronic, a medical equipment manufacturer, said it would buy intersect ent for us $936.2 million in cash to strengthen its otolaryngology surgery products. Complementary product lines and customer base will further promote Medtronic’s efforts to bring positive impact to patients with chronic sinusitis (CRS). Intersect ent’s sinus implants named propel and sinuva are clinically proven solutions that open sinus channels and deliver anti-inflammatory steroids to help heal.
|Modena’s share price fluctuated violently and was accused of unreasonable market value
Since the outbreak of the epidemic crisis in 2020, Moderna, which developed mRNA vaccine technology, has become the target of Wall Street capital. With the entry of a large amount of funds, Modena’s share price has soared 1778.74% from the low point at the beginning of last year, and has risen 268.97% since 2021, while the S & P 500 index has risen only 18% in the same period. Bank of America said that Moderna’s share price may fall sharply in the future, because its market value of nearly $200 billion once exceeded that of old pharmaceutical giants MSD and Bristol Myers Squibb. This performance is “unreasonable from a fundamental point of view”, reiterating that its target price is $115, which means that there is still a lot of room for decline.
|Novavax new crown vaccine single dose booster needle can increase the titer of functional antibody by 4.6 times
According to the preliminary test data released by Novavax, Inc., six months after the completion of the first two doses of the company’s recombinant nanoparticle protein new crown vaccine nvx-cov2373 adjuvanted by matrix-m, the titer of functional antibody can be increased by 4.6 times by administering a single dose of booster injection. In addition, the cross reaction of functional ACE-2 binding inhibition antibody against Delta (b.1.617.2) variant was more than 6 times higher than that after the first round of inoculation.
|For Delta and other mutants! Domestic new crown vaccine of pickup truck was the first to start clinical trials in developed countries
Yisheng biopharmaceutical Limited announced that the New Coronavirus milepost recombinant New Coronavirus vaccine (CHO cell, S protein), which was independently developed by the biotech company, was approved by the New Zealand medicines and medical devices safety authority for the first phase of clinical trials. This is another milestone after the recent clinical approval from the Ministry of health and prevention of the United Arab Emirates. Following the completion of the relevant clinical studies of the biotech project, the emergency use authorization and product number application of New Coronavirus vaccine for pickup recombinant protein were carried out in several countries. Preclinical studies show that the vaccine is expected to become a universal vaccine with dual functions of prevention and treatment.
|Yanyeyi plans to build a supply system of more than 1 million doses of Xinguan oral drugs within this year
Japanese pharmaceutical company Yee Yee Yi pharmaceutical, said that the development of COVID-19 oral medicine, will be in 2021 to build more than 1 million supply system. It is also considered to apply for the special “conditional early approval” set by the Japanese government for new drug development within this year, which will deal with the early supply after approval. If the oral drugs that mild patients can take at home can be put into practice, it will help to alleviate the tension of the medical system. Yanye’s therapeutic candidate will block the function of the enzymes required for virus reproduction. Imagine taking it once a day for 5 consecutive days. Drugs will be used in the early stage of infection to curb the severity and improve the symptoms of fever and cough. Yanye also held consultations with the U.S. Department of health and social welfare with the goal of supplying overseas goods.
|Boehringer Ingelheim, Taikang and xinruipeng create pet insurance
At the first “unlimited creation, boundless pet” Pengbo creation and enjoyment day jointly created by Boehringer Ingelheim and xinruipeng pet medical group, Boehringer announced to reach a pet insurance strategic cooperation with Taikang online and xinruipeng group. The three parties will jointly develop pet insurance and explore innovative solutions for pet medical and health insurance in the Internet Era. The three party cooperation model, which is the first in China, combines pet medicine, pet medical institutions and all the advantages of pet insurance to achieve the upstream and downstream of Internet plus pet insurance products, optimize the experience of pet and pet owners, enhance pet medical standards and professional standards, and promote the sustainable development of pet health industry.
Biontech. In the second quarter of 2021, the revenue was 5.308.5 billion euros, compared with 41.7 million euros in the same period last year; The quarterly net profit was 2787.2 million euros, compared with a net loss of 88.3 million euros in the same period last year.
Thermo Fisher. In the second quarter of fiscal year 2021, the net profit attributable to common shareholders of the parent company was US $1.828 billion, a year-on-year increase of 58.13%; The operating revenue was USD 9.273 billion, a year-on-year increase of 34.06%.
Perkin Elmer. In fiscal year 2021, the net profit attributable to the common shareholders of the parent company was US $625 million, a year-on-year increase of 266%; The operating revenue was USD 2.536 billion, a year-on-year increase of 73.22%.
Yaming Kant. In the first half of 2021, the operating revenue increased strongly by 45.7% year-on-year to RMB 10.537 billion. China’s laboratory service revenue increased by 45.2% year-on-year to 5.487 billion yuan. Cdmo service revenue increased by 66.5% year-on-year to about 3.599 billion yuan. The laboratory service revenue in the United States decreased by 15.7% year-on-year to 659 million yuan. The revenue of clinical research and other cro services increased by 56.5% year-on-year to 783 million yuan. Adjusted EBITDA was RMB 3.649 billion, a year-on-year increase of 53.4%. The net profit attributable to shareholders of listed companies was 2.675 billion yuan, a year-on-year increase of 55.8%.
Then Ding medicine. The net product revenue in the second quarter of 2021 was $36.9 million, and the revenue in the same period of 2020 was $11 million. Among them, zele’s sales revenue is US $23.4 million (US $7.5 million in the same period in 2020), epdun’s sales revenue is US $9.5 million (US $3.5 million in the same period in 2020) and Qingle’s sales revenue is US $4 million (no revenue in the same period in 2020). For the three months ended June 30, 2021, the net loss of zaiding pharmaceutical was US $163.3 million, and the net loss for the same period in 2020 was US $80.6 million.
Artificial intelligence medical enterprises assume that medical has started the listing process in Hong Kong recently, and officially submit the prospectus to the Hong Kong Stock Exchange as soon as this month. Established in 2016, hypothetical medical mainly uses artificial intelligence software to analyze medical image data such as Dr, CT and MRI, so as to provide doctors with accurate and efficient auxiliary diagnostic tools and provide the accuracy of medical diagnosis. The main products of hypothetical medicine include inferread artificial intelligence auxiliary diagnosis products, inferscholar artificial intelligence scholar scientific research platform, etc.